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Challenging metastatic breast cancer with the
natural defensin PvD1†
Tiago N.Q1 Figueira, ‡a Filipa D. Oliveira, ‡a Inês Almeida,a Érica O. Mello,b
Valdirene M. Gomes,b Miguel A. R. B. Castanho *a and Diana Gaspar *a
Metastatic breast cancer is a very serious life threatening condition that poses many challenges for the
pharmaceutical development of effective chemotherapeutics. As the therapeutics targeted to the loca-
lized masses in breast improve, metastatic lesions in the brain slowly increase in their incidence compro-
mising successful treatment outcomes overall. The blood–brain-barrier (BBB) is one important obstacle
for the management of breast cancer brain metastases. New therapeutic approaches are in demand for
overcoming the BBB’s breaching by breast tumor cells. In this work we demonstrate the potential dual role of
a natural antimicrobial plant defensin, PvD1: it interferes with the formation of solid tumors in the breast
and concomitantly controls adhesion of breast cancer cells to human brain endothelial cells. We have
used a combination of techniques that probe PvD1’s effect at the single cell level and reveal that this
peptide can effectively damage breast tumor cells, leaving healthy breast and brain cells unaffected.
Results suggest that PvD1 quickly internalizes in cancer cells but remains located in the membrane of
normal cells with no significant damage to its structure and biomechanical properties. These interactions
in turn modulate cell adhesiveness between tumor and BBB cells. PvD1 is a potential template for the
design of innovative pharmacological approaches for metastatic breast cancer treatment: the manipu-
lation of the biomechanical properties of tumor cells that ultimately prevent their attachment to the BBB.
Introduction
Breast cancer is an invasive malignancy most commonly diag-
nosed in women and the second leading cause of cancer-
related death in women worldwide.1,2 Conventional cancer
chemotherapy lacks specificity against tumor cells and dis-
plays low intracellular delivery efficacy. Additionally, severe
side effects resulting from the unspecific cellular uptake by
normal tissues and the development of resistance phenomena
puts patients at a high risk of relapse.3,4 Despite the many
obstacles involved in the application of conventional che-
motherapeutic strategies, these have been successful in
increasing the lifespan of patients with breast cancer.5
However, this increase in overall survival has been paired with
an increase in the incidence of metastatic cancer. As clinicians
are in better control of the breast disease, lesions outside the
breast have time to develop.5–7 In fact, metastatic breast cancer
accounts for most of the cancer deaths in breast cancer
disease8 and studies show that 10–16% of patients with disse-
minated breast cancer disease present lesions at the central
nervous system (CNS), a percentage that can grow up to 30%
after autopsy.9,10 CNS relapse of patients with metastatic triple-
negative breast cancer (TNBC) is particularly high.11
Challenges for breast cancer disease and respective brain
metastatic lesions’ management reside in the need for devel-
oping drugs that can recognize cancer cells and accumulate
efficiently intracellularly. The treatment of brain metastasis by
chemotherapy is, however, further compromised due to the
inability of therapeutics to penetrate the blood–brain barrier
(BBB) and accumulate in intracranial tissues.5,12 In addition to
the low passive paracellular permeability, the BBB cells express
high levels of drug transporters that mediate drug efflux and
consequently the brain is a protected location for malignant
cells to settle and proliferate.13,14 Other therapeutic options
rely on whole brain radiotherapy and stereotactic radiotherapy,
which have been correlated with cognitive impairment and
surgical resection when multiple intracranial lesions are
found, also with limited success.15–17 Developing methods that
can result in improved BBB penetration of drugs and their
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availability in brain sites is of utmost importance and an
urgent necessity. Peptide-based therapies have emerged as a
pool of new strategies capable of overcoming unspecific target-
ing and resistance issues. Antimicrobial peptides (AMPs) with
anticancer activity (anticancer peptides, ACPs) have been
shown to exert effects directly on cancer cells18 and of being
capable of interfering with angiogenesis, gene expression and
apoptosis, among other mechanisms.19 Many natural AMPs
have anticancer activities and have thus been explored as tem-
plates for drug design.20–22 Our group has previously reported
the apoptotic activity of the AMP human neutrophil peptide-1,
HNP-1, on prostate cancer cells23 highlighting ACPs’ potential
in blocking the metastatic cascade. In the present work, we
reveal the antitumor activity of PvD1 peptide, an AMP defensin
from Phaseolus vulgaris, the common bean,24,25 on human
breast cancer cells and its ability in aiding the prevention of
brain metastasis formation by affecting cellular adhesion. By
using a combination of spectroscopic, fluorescence and
imaging techniques we show that PvD1 peptide acts directly on
cancer cells from the primary tumor location and directly on
the adhesion of breast cancer cells to the endothelial cells
from the human BBB without significant impact on cells from
normal tissue. By understanding the cellular and molecular
interactions occurring in the initial moments of cell–cell
contact, an alternative mechanism of action for anticancer
treatment is envisioned based on the prevention of the meta-
static cells’ BBB crossing and reaching into the brain parench-
yma. At the same time, a new avenue for the role of diet nutra-
ceuticals in breast cancer therapy is open.
Experimental
Reagents
Human neutrophil peptide-1 (HNP-1; Ala-Cys-Tyr-Cys-Arg-Ile-
Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-
Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys: Cys2-Cys30, Cys4-Cys19,
Cys9-Cys29) was purchased from Bachem. Adherent cell lines
MDA-MB-231 and MCF 10A were purchased from American
Type Culture Collection (ATCC, HTB-26 and CRL-110317
respectively). HBMEC (human brain microvascular endothelial
cells) isolated by ScienCell Research Laboratories from human
brain tissue and respective media and supplements were pur-
chased from Innoprot. DMEM media, heat-inactivated fetal
bovine serum (FBS), penicillin and streptomycin solution, and
trypsin (TrypLE Express enzyme) were obtained from Life
Technologies. Mammary Epithelial Basal Medium (MEBM)
and SingleQuots (hydrocortisone, bovine pituitary extract
(BPE), epidermal growth factor human recombined (rhEGF),
and recombinant human insulin) were purchased as clonetics
MEGM™ BulletKit™ from Lonza, Ltd. Cholera toxin from
Vibrio cholera, trypsin inhibitor from Glycine max (soybean),
glutaraldehyde solution (50% in water), bovine-serum albumin
biotinamidocaproyl labeled (biotin-BSA), streptavidin, con-
canavalin A (ConA, biotin conjugate) and dimethyl sulfoxide
(DMSO) were obtained from Sigma-Aldrich. MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) salt was
obtained from Invitrogen™ (Carlsbad, CA, USA) and 4-(2-[6-
(dioctylamino)-2-naphthalenyl]ethenyl)-1-(3-sulfopropyl)pyridi-
nium inner salt (di-8-ANEPPS) probe was purchased from
Sigma-Aldrich.
PvD1 peptide
The purification of PvD1, the defensin from Phaseolus vulgaris
(cv. Pérola) seeds, was performed as described by Games
et al.24 For the protein extraction, P. vulgaris seeds were pilled
and the cotyledons were ground to a fine flour which was
mixed with phosphate buffer (10 mM Na2HPO4; 15 mM
NaH2PO4; 100 mM KCl; 1.5% EDTA) pH 5.4 at a 1 : 5 ratio
(flour : extraction buffer) and stirred for 2 h at 4 °C. This hom-
ogenate was centrifuged (15 000g, 20 min at 4 °C) and the
supernatant was subjected to ammonium sulfate precipitation
at 70% saturation. After centrifugation, the precipitate was
solubilized in distilled water and heated at 80 °C for 15 min.
This protein extract was then centrifuged (10 000g, 8 min at
4 °C) and the obtained supernatant was dialyzed against dis-
tilled water and recovered by freeze drying for further purifi-
cation of PvD1. Initially an anion-exchange DEAE-Sepharose
column was employed. The sample was firstly eluted in the
equilibration buffer Tris-HCl 20 mM, pH 8.0 and then in a
Tris-HCl buffer added with 1 M NaCl. These chromatographic
steps were performed at a flow rate of 60 mL h−1 (LKB pump
P-1, Pharmacia). The absorbance of the fractions was read on a
spectrophotometer at 280 nm. The D1 fraction, the non-
retained fraction derived from the previous anion-exchange
chromatography on a DEAE-Sepharose column, was solubil-
ized in 0.1% TFA and 500 μL were injected into the C18 reverse
phase column. Chromatography was performed at a flow rate
of 0.5 mL min−1 with 100% solvent A (0.1% TFA and 2% aceto-
nitrile) for 10 min, 0–100% solvent B (80% acetonitrile con-
taining 0.1% TFA) over 30 min, 100% solvent B over 5 min and
finally 100% solvent A for the remaining time. Proteins were
monitored by on-line measurement of the absorbance at
220 nm. The peak corresponding to the PvD1 was collected.
Cell culture
MDA-MB-231 adherent human breast cancer cells were cul-
tured as a monolayer in DMEM supplemented with 10% FBS
and 1% penicillin–streptomycin. MCF 10A human breast cells
were cultured as a monolayer in MEBM supplemented with
the respective SingleQuots according to manufacturer’s
instructions, cholera toxin 100 ng ml−1 and 1% penicillin–
streptomycin. Human Brain Microvascular Endothelial
Cells (HBMEC) were cultured in fibronectin (FN)-coated flasks
(2 µg cm−2) in endothelial cell basal medium with 5% FBS, 1%
penicillin–streptomycin and 1% endothelial cell growth sup-
plement. All cultures were maintained at 37 °C and 5% CO2 in
a humidified environment.
Cellular proliferation assay
An MTT assay was used for evaluating the in vitro cytotoxic
activity of HNP-1 and PvD1 peptides as previously described.
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MDA-MB-231 and MCF 10A cells were seeded at 3000 cells per
100 μL per well and 50 000 cells per 100 µL per well, respect-
ively, into a 96-well plate and incubated for 24 h. HBMEC were
seeded at 5000 cells per 100 µL per well into 96-well plates
coated with FN (2 µg cm−2) and incubated also for 24 h. After
media removal, 100 μL of the peptide solution prepared in
complete serum-free medium and ranging from 0.01–100 μM
for PvD1 and 0.1–100 µM for HNP-1 was added to the wells.
After a 24 h incubation period with the peptides, 10 µL of
5 mg ml−1 MTT solution was added to each well following a
2 h incubation. The medium containing peptide and MTT was
then removed and 150 µL of DMSO (spectrophotometric grade)
was added for solubilisation of the formed formazan crystals.
Absorbance was measured at 540 nm. Serum-free medium, 20%
DMSO-containing medium and 30% DMSO-containing medium
were used as controls for 100% cell viability (untreated cells)
and negative controls for breast tumor cells/HBMEC and
breast normal cells, respectively.
Cell viability (%) was determined as:
(Absorbancepeptide-treated cells/Absorbanceuntreated cells) × 100 and
cell death (%) as: 100 − (percent viability). IC50 values were
determined using the Graphpad 6.0 software package using a
log(inhibitor) vs. normalized response. Experiments were
performed on different days using independently grown cell
cultures.
Atomic force microscopy imaging
AFM imaging was performed with a JPK Nano Wizard II
(Berlin, Germany) mounted on a Zeiss Axiovert 200 inverted
microscope (Carl Zeiss, Germany). The AFM head is equipped
with a 15 µm z-range linearized piezoelectric scanner and an
infrared laser. Human breast tumor cells were cultured at 1 ×
104 cells per ml while human breast non-tumor cells were
seeded at 1 × 105 cells per ml into 40 mm tissue culture dishes
(TPP) for 24 h. HBMEC were cultured at 1 × 104 cells per ml
into 40 mm tissue culture dishes previously coated with FN
(2 µg cm−2). Cells were washed with phosphate buffered saline
(PBS) solution and serum-free medium containing PvD1 and
HNP-1 was added. Control cells were prepared with serum-free
medium only. After a 24 h incubation cell medium was removed
and cells were washed with PBS solution and incubated with a
1% glutaraldehyde solution for 10 minutes (room temperature),
washed with PBS and sterile milli-Q water and finally air-dried.
Images were obtained in air using intermittent contact and
contact mode. Uncoated silicon ACL cantilevers from AppNano
with typical resonance frequencies ranging between 145–230
kHz and an average spring constant of 45 N m−1 were used.
Scan speeds were lower than 1 Hz and total areas with 100 ×
100 μm were scanned with a 512 × 512 pixel resolution. Height
and error images were recorded and line fitted as required.
The presented cell height corresponds to the difference
between the bottom and the highest point of each cell and the
maximum cell height was acquired after drawing height pro-
files for each cell using JPK SPM Data Processing version 5.1.8.
The total number of analyzed cells was 135, 151 and 59 for
MDA-MB-231, MCF 10A and HBMEC respectively. The surface
roughness for control and treated cells was defined as the root-
mean-square roughness (Rms) obtained from AFM height
images. Gwyddion software version 2.3327 was used for the
determination. Rms values were obtained from squared areas
of 2.5 × 2.5 μm in the nucleus and cytoplasm areas. The Rms
average of groups of five squares corresponds to the Rms value
of each cellular component, nuclei and cytoplasm, within each
cell. Final Rms values correspond to averages obtained for a total
number of 54, 51 and 50 cells for MDA-MB-231, MCF 10A and
HBMEC respectively. Cells were observed and imaged through
two to three different days using independently grown cultures.
Zeta potential measurements of live human breast and
microvascular endothelial cells (HBMEC) in the presence of
the PvD1 peptide
Confluent human breast and endothelial brain cells were
washed after trypsinization and diluted in PBS buffer to 1 ×
105 cells per ml and 2.5 × 105 cells per ml, respectively. Cell
suspensions with and without PvD1 (0.01–50 µM) were added
into disposable zeta cells with gold electrodes and allowed to
equilibrate for 30 minutes at 37 °C. Each experiment consisted
of 10–15 measurements with ∼40–70 runs performed at a con-
stant voltage (40 V) using a Zetasizer Nano ZS. The complete
experiment was carried out at least two times using inde-
pendent cellular suspensions.
Di-8-ANEPPSs labelling of live human breast and
microvascular endothelial cells and fluorescence spectroscopy
evaluation in the presence of PvD1
Cells from human breast and brain were washed, suspended in
PBS buffer and incubated with 30 µM of di-8-ANEPPS. The cells
were allowed to incorporate the fluorescent probe for 1 h at room
temperature at constant rotation, and were then washed to
remove non-incorporated di-8-ANEPPS and suspended to a final
concentration of 5 × 105 cells per ml. Cell membrane dipole
potential variations in the presence of PvD1 were examined
through di-8-ANEPPS fluorescence excitation spectrum shifts.
Di-8-ANEPPS fluorescence excitation spectra were collected
on an Edinburgh FLS920 spectrofluorimeter (Livingston, UK).
The emission wavelength, λemi, was set to 670 nm to avoid
membrane fluidity artifacts,28 and individual spectra were
retrieved between 380 and 580 nm in the absence and pres-
ence of PvD1 (10 minute incubation). Excitation spectra were
corrected for background intensity. Differential spectra were
obtained by subtracting the normalized excitation spectra (to
the spectrum integral) of the suspended labeled cells in the
presence of PvD1 from the control spectra, obtained in the
absence of the peptide.29 To quantify di-8-ANEPPS spectral
shifts, excitation intensity ratios (R) were calculated through the
relationship R = [Iexc(λa)]/[Iexc(λb)], where λa and λb correspond
to the wavelengths with the highest absolute intensity differ-
ence (differential spectrum minimum or maximum). For a
correct interpretation, λa and λb should be lower and higher
than the maximum excitation wavelength, respectively. The
intensity ratios normalized to the control R (Rnorm) were used
as a quantitative parameter of di-8-ANEPPS spectral shifts and
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correlate with variations in the cell membrane dipole poten-
tial. This experiment was repeated on two different days using
independently grown cell cultures.
Atomic force microscopy-single cell force spectroscopy
(AFM-SCFS)
AFM setup. A NanoWizard II AFM from JPK Instruments
(Berlin, Germany) mounted on the top of an Axiovert 200
inverted microscope (Carl Zeiss, Germany) was used which was
coupled with a CellHesion module (JPK Instruments) for
extending the vertical range of the AFM from 15 µm to
100 µm. Experiments were conducted at constant temperature,
25 °C, using a temperature-controlled BioCell sample chamber
from JPK Instruments.
Cantilever coating. SCFS measurements were performed
using tipless arrow TL1 cantilevers (Nanoworld, Neuchatel,
Switzerland) with a nominal spring constant of 0.03 N m−1.
Cantilevers were cleaned for 15 minutes with UV light and then
coated with biotin BSA-ConA-streptavidin as previously
described.30 Briefly, after a PBS rinse, cantilevers were incubated
overnight with a biotin-BSA solution (0.5 mg ml−1) at 37 °C
under a humidified atmosphere, rinsed with PBS, incubated for
30 minutes at room temperature under a humidified atmosphere
with streptavidin (0.5 mg ml−1), rinsed again with PBS and incu-
bated 30 minutes with a ConA-biotin solution (0.4 mg ml−1)
maintaining conditions. Cantilevers were coated for each day of
measurement, kept in PBS buffer until use and calibrated using
the inbuilt thermal noise method before each experiment.
Cell culture
Breast tumor cells and HBMEC were grown onto coverslips
(FN coated at 2 µg cm−2 for HBMEC) at 1 × 104 cells per ml for
24 h. Control and PvD1-treated cells were prepared as
described for AFM experiment imaging but kept without
fixation procedures for further use in SCFS experiments.
Cell capture
Isolated cell suspensions of breast tumor and brain endothelial
cells were obtained from confluent cells cultured in separated
flasks, before each experiment, without trypsinization and after
30 minutes of incubation in PBS. Detached cells were washed,
suspended in serum-free medium and incubated for 15 minutes
at 37 °C with agitation for recovering of the collection pro-
ceduresQ2 . Cells grown over the coverslips were mounted on the
BioCell chamber and kept within serum-free medium. Around
103 harvested cells were injected into the chamber and allowed to
settle for a few seconds. Cell capture was performed by position-
ing a ConA-biotin-coated cantilever over a settled breast tumor or
brain endothelial cell and establishing contact for 30 seconds.
The cantilever with the captured cell was slowly retracted and the
attached cell was allowed to rest and establish firm contact with
the cantilever for 5 minutes away from the surface.
Cell–cell adhesion experiments. Cell–cell contact was pro-
moted at constant height with a speed of 2 µm s−1, in closed-
loop mode and with an applied force of 0.5 nN. Contact time
was 5 seconds and the cantilever was further retracted with a
z-range displacement of 70 μm to guarantee complete cell separ-
ation. One to five force–distance curves were obtained for each
contact with a 10 second interval between each curve and
30 second interval between the cells probed. Detachment force
(FD), detachment work (WD) and tether extraction forces were
obtained from the retraction force curves using the Image
Processing Software 5.1.8 (JPK Instruments, Berlin, Germany).
Data sets were generated using between 16 and 28 cells.
Cantilever cell-bound and coverslip cell-attached morphology was
constantly assessed during experiments to guarantee viability.
Statistical analysis. Quantitative data were processed using
Excel 2007 (Microsoft, USA) and the GraphPad Prism 6.0 soft-
ware package. Medians, means and standard deviations are
shown in the figures. Pairwise significances were calculated
using one-way ANOVA followed by Tukey’s multiple compari-
son test, and nonparametric Mann–Whitney, Kruskal–Wallis
and two-tailed unpaired t-tests.
Fig. 1 In vitro cytotoxicity of PvD1 and HNP-1 toward human breast
cells. The cytotoxic activity of PvD1 and HNP-1 was tested using
MDA-MB-231 breast adenocarcinoma cells (A) and MCF 10A breast epi-
thelial cells (B). All experiments were repeated on different days using
independently grown cell cultures.
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Fig. 2 Cell morphological examination of human breast cells using atomic force microscopy (AFM). Representative AFM height images of human
breast cells in the absence (A) and the presence of PvD1 (B) and HNP-1 (E). Control cells present epithelial morphology that change in the presence
of both peptides. Representative cell height profiles and cell height normalized to control determined before and after PvD1 and HNP-1 contact are
shown (C, D, F, G). The number of analysed cells for the determination of MDA-MB-231 cell height in the presence of PvD1 was: 0 μM – 45; 0.01 μM
– 22; 0.8 μM – 33 and 50 μM – 23 while for the MFC 10A cell line: 0 μM – 28; 0.01 μM – 45; 0.8 μM – 41 and 50 μM – 25. Cell height determination
in the presence of HNP-1 was based on 12 cells for both cell lines.
Nanoscale Paper


























Developing more effective and selective anticancer drugs
remains one of the greatest and most urgent challenges in
medicine. Whereas early and more effective diagnostics
coupled with current therapies are increasingly successful,
metastatic disease increases cancer incidence. TNBC, for
instance, has high metastatic ability to the CNS. In fact, most
of brain metastases seen in patients have their origin in malig-
nant melanoma, lung and breast cancers.31 These patients
need a chemotherapeutic agent that reaches the brain par-
enchyma for targeting these metastatic lesions.
PvD1 peptide is an efficient ACP against breast tumor cells and
acts on an intracellular target
The in vitro activity of both PvD1 and HNP-1 was studied using
one breast cancer cell line: MDA-MB-231 (breast adeno-
carcinoma) and one normal human cell line: MCF 10A (breast
epithelial cells). Cell lines were exposed to increasing concen-
trations of peptides for 24 h (Fig. 1). MTT assay resulted in
IC50 values of 0.82 ± 0.14 and 15.2 ± 1.6 μM for PvD1 and
HNP-1 respectively, against the cancer cell line. The selectivity
of both peptides was further investigated using healthy breast
cells revealing an IC50 value of 13.3 ± 1.8 μM for HNP-1. The
curve obtained for PvD1-normal breast cell assay deviated sig-
nificantly from the typical sigmoidal profile: cell death is only
weakly dependent on concentration and 100% cell death was
not reached within the range of concentrations tested. Overall,
PvD1 shows much higher efficacy towards breast cancer cells
when compared with the standard reference defensin HNP-1
and other ACPs.18,32
AFM is a technique of excellence for observing changes in
cells with nanometre resolution33,34 and was used for a mor-
phological and topographical examination of the reference
standard defensin HNP-1 and PvD1 peptides’ effect on tumor
and normal breast cells. Representative AFM height images
and respective 3D projections are presented in Fig. 2. The
results show a higher efficacy of PvD1. Tumor and normal
breast cells show an epithelial morphology and variable
dimensions (Fig. 2A) with a similar topography as expected.35
An intact surface is observed with pseudopodia and filopodia
in the case of tumor cells (structures associated with high inva-
sive potential) while normal cells show no evidence of these
structures. Increasing PvD1’s concentration results in damage
of the breast tumor cells characterized by nuclear collapse, cell
shrinkage and visibility of the cytoskeleton structure (Fig. 2B)
concomitant with changes in height (Fig. 2C). No alterations
were observed however at the membrane roughness (Rms) level
(Fig. S1†). In normal breast cells PvD1 effects appear to be atte-
nuated with no observed changes in the cell height and cell
membrane roughness (Fig. 2D and S1†). Considering that the
cytoskeleton, in addition to acting as the cell backbone, is also
responsible for maintaining the lipid bilayer integrity,36
changes observed in the cell height and the maintenance of
Rms support the hypothesis that despite the peptide’s aggressive-
ness towards tumor cells, cellular structure and integrity are
partially retained. Consequently, PvD1 activity must result from
an intracellular target.
The effects of HNP-1 on breast cells are also depicted in
Fig. 2E–G. At concentrations below the IC50 visible morpho-
logical alterations occur in the tumor cells. Changes in the
nuclear area reveal nuclear collapse supported by variation of
Fig. 3 In vitro cytotoxicity of PvD1 toward human brain microvascular
endothelial cells (HBMEC) and cellular characterization by atomic force
microscopy (AFM). The cytotoxic activity of PvD1 was additionally tested
using HBMEC (A). PvD1’s effects on HBMEC were also investigated by
AFM at the single cell level. Representative AFM height images of
HBMEC in the absence and presence of PvD1 are shown which reveal a
selective activity for the peptide (B).
Paper Nanoscale

























cell height profiles (Fig. 2F). Cytoskeleton changes are also
evident as the cell backbone becomes visible. We could also
observe small solid structures near the nuclear area of the
cells, characteristic of apoptotic bodies.37 No significant
changes were observed at the cell membrane roughness level
when compared with the untreated control cells (Fig. S1†).
Normal breast cells treated with HNP-1 at low concentrations
showed important morphological defects. Cells appeared
shrunk with their cytoskeleton structure evident, however no
changes in the cell height and membrane roughness were
observed (Fig. 2G and S1†). Increasing concentrations of
HNP-1 led to severe cellular damage that compromised a
detailed examination of the different cellular parameters used
for evaluating the peptide’s activity.
PvD1 interacts with human breast and brain cellular mem-
branes resulting in reduced cytotoxic activity and cellular
damage of the human brain cells
After studying PvD1 effects at the breast tumor level, we further
explored the effects of this peptide directly on human brain
microvascular endothelial cells. The cell proliferation assay result
is similar to the one obtained in MCF 10A cells (Fig. 3A), with
50% cell death at ∼7 μM.
AFM analyses of HBMEC in the presence of PvD1 revealed
the reduced impact that the peptide has over cell morphology
and topography. In the absence of PvD1 cells appear elongated
with a distinct nuclear area (Fig. 3B). The presence of the
peptide allows the visualization of the cytoskeleton structure
whereas nuclear condensation and fragmentation is also
observed. PvD1 concentrations near 50 µM, induce changes in
cell shape and accentuate nuclear damage. These changes are
however accompanied by no alterations in cell membrane
roughness or the maximum cell height (Fig. S2†). Despite the
observed low cell damage induced by PvD1, a peptide–mem-
brane interaction cannot be excluded at this point and so PvD1
interaction with tumor and normal cell membranes was
assessed by zeta potential and fluorescence spectroscopy tech-
niques in the absence and presence of increasing peptide con-
centrations (Fig. 4 and S3†).
Mean values obtained for the surface zeta potential of
breast cancer cells, breast normal cells and brain endothelial
cells were −22.99 ± 2.75; −25.0 ± 0.87 mV and −12.86 ± 0.74,
respectively (Fig. 4B and C). The obtained HBMEC’s mem-
brane surface charge value is similar to the one reported by
our group for bovine endothelial cells (BCEC)38 and to the one
we obtained for a primary culture of HBMECs (−13.73 ±
0.78 mV, data not shown) cultured as described by Bernas and
co-workers.39 The presence of zwitterionic phospholipids in
normal cells contributes to an overall neutral charge19,40 of the
membrane but zeta potential reports on the electrostatic
potential formed at the slipping plane of the cell32 and conse-
quently results from an overall charge for which not only the
Fig. 4 Cell membrane surface charge of human breast and brain microvascular endothelial cells in the presence of PvD1 and changes in the dipole
potential of human brain cells’ membranes. PvD1 peptide effects on the cell membrane charge density of HBMEC (A), MCF 10A (B), and
MDA-MB-231 (C) cells were followed by zeta potential measurements. All experiments were repeated on different days using independently grown
cell cultures. A one-way ANOVA followed by a Tukey post hoc test was employed. *0.01 < p-value < 0.05; ****p-value < 0.0001. Variations in the cell
membrane dipole potential of HBMEC in the presence of PvD1 were also followed by di-8-ANEPPS fluorescence excitation spectra shifts (D, E). This
voltage sensitive probe incorporates into the outer leaflet of the cellular membrane and is sensitive to changes in the local electric field derived
from the alignment of water and lipid headgroup dipoles. Differential spectra were obtained by subtracting the normalized excitation spectra (to the
integrated spectrum areas) of the suspended labeled cells in the presence of increasing PvD1 concentration from the spectra obtained in the
absence of PvD1 (D). For clarity, a smoothened differential excitation spectrum is presented for each condition. The normalized excitation intensity
ratios, Rnorm, determined at different PvD1 concentrations, are shown (E). This ratiometric analysis was used to quantify the extent of di-8-ANEPPS
spectra deviation and, consequently, the magnitude of membrane dipole perturbation. All experiments were repeated on different days using inde-
pendently grown cell cultures. Statistical significance was evaluated with an unpaired two-tailed t-test. *0.01 < p-value < 0.05; ****p-value < 0.0001.
Nanoscale Paper

























lipid headgroups of the membrane bilayer contribute but also
ions and charged proteins.38 The anionic character of the BBB
is a key feature for selective crossing of cationic molecules into
the brain.38 The loss of lipid asymmetry leads to the accumu-
lation of phosphatidylserine (PS) phospholipid at the outer
leaflet of the membrane bilayer of tumor cells and also the
overexpression of O-glycosylated mucins, glycosaminoglycans
(GAGs) and accumulation of sialic acid (SA) residues is
expected.19,41,42 MCF 10A epithelial cells are positive for sialo-
mucins, cytokeratins and milk fat globe antigen and even
though they may display a neutral net charge on the plasma
membrane, the presence of sialomucins can strongly contrib-
ute to the high negative surface charge value measured.
Zeta potential variation results revealed a marked affinity of
PvD1 for breast cell membranes (Fig. 4B and C). PvD1 interacts
with both types of breast cells permeabilizing the membrane and
not leading to complete surface charge neutralization. For
HBMEC, changes in the surface charge density were only
observed at high peptide concentrations (Fig. 4A), in which more
than 60% of the cells were non-viable. High PvD1 concentration
is needed to significantly affect zeta potential values but cell
death occurs without full neutralization of the membrane
charge, such as we have previously described for other ACPs.23,32
Mechanistic insights into peptide–membrane interaction
were further obtained after labelling live HBMEC and breast
cells with the voltage-sensitive dye, di-8-ANEPPS. This fluo-
rescent probe is incorporated into the outer leaflet of the cellu-
lar membranes and senses the local electric field derived
from the alignment of water and lipid headgroup dipoles.43
Fig. 4 and S3† show the differential excitation spectra of di-8-
ANEPPS in HBMEC, normal breast cells and cancer breast
cells, at three different concentrations of PvD1, as well as
Rnorm. PvD1 interacts with HBMEC in a way that perturbs
membrane potential, i.e. inserting into the lipid bilayer.
Interaction with breast cells is more superficial as the dye does
not report the presence of the defensin. The accumulation of
this peptide in the membrane is not sufficient to induce severe
damage to the cell membrane. Similar to HBMEC, MCF 10A
and MDA-MB-231 cells are capable of attracting PvD1 to their
surface. The higher negative membrane surface charge com-
pared with HBMEC allows a significant change in zeta poten-
tial values for the breast cells. The partial accumulation of the
peptide in the surface of the lipid bilayer of non-tumor breast
cells results in transient changes of the membranes’ dipole
potential which are not reported by the hydrophobic dye.
Cell-to-cell adhesion as a potential control point to target
brain metastasis. Correlation with PvD1–cellular membrane
interaction
Metastatic breast cancer cells transmigrate through the layer of
endothelial cells of brain capillaries before settling in the
brain.31 In addition to protecting the brain, the BBB also pro-
tects metastatic cells in the processes of extravasation and
multiplication11,31 by actively helping cancer cells to reach the
brain parenchyma and providing an optimum medium for
further proliferation.11 The cellular and molecular mecha-
nisms underlying the interaction of metastatic cells with brain
endothelial cells are important during these events but remain
largely unknown. The characterization of this interaction
should however occur at the early steps of cell–cell interaction
since metastatic brain tropism relies on the first contact.44
Adhesion plays important roles in cell communication and
regulation of signalling pathways in cancer45–47 and its
changes result in perturbations on biophysical and biochemi-
cal cellular processes necessary to maintain cell homeostasis.
Many techniques have been used to measure cell adhesion
and these can be applied to a cell population or in a single cell
approach.47–49 Allowing the measurement of forces in the pN
to nN range with a displacement of sub-nm to µm under near
physiological conditions,30,50 AFM represents an ideal method
for characterizing cell-to-cell interactions.46
We tested PvD1 ability to interfere with cell-to-cell adhesion
in breast cancer cells and attachment of cancer cells to brain
endothelial cells using AFM-SCFS (Fig. 5, S4 and S5†). A single
living cell was captured with a biotin BSA-ConA-streptavidin
coated tipless cantilever which converted the cell into a probe
for making contact with other cells. MDA-MB-231 tumor cells
were attached to cantilevers as described previously and
approached to MDA-MB-231 and PvD1-treated cells. The
contact was maintained for 5 seconds with a constant force of
0.5 nN. Cell detachment was recorded during retraction of the
Fig. 5 Cell-to-cell adhesion investigated by atomic force microscopy-
based-single cell force spectroscopy (AFM-SCFS). PvD1 perturbs cell-to-
cell adhesion between breast tumor cells and endothelial cells.
Adhesion strength (FD, left graph) and work (WD, right graph) in the
absence and presence of peptide are presented for MDA-MB-231 cells –
MDA-MB-231-cantilever bound cells (A) and HBMEC – MDA-MB-231-
cantilever bound cells (B). 16 to 28 cells were analyzed and the number
of force–distance curves obtained for each peptide concentration
tested was: (A) 0 µM – 65; 0.01 µM – 63; 0.8 µM – 47 and 50 µM – 54;
(B) 0 µM – 97; 0.1 µM – 123; 0.8 µM – 63 and 2.5 µM – 59.
Statistical significance was evaluated with a Kruskal–Wallis test. *0.01 <
p-value < 0.05; **0.001 < p-value < 0.01; ***0.0001 < p-value < 0.001;
****p-value < 0.0001.
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cantilever (force–distance, F–d curves, Fig. S4†); adhesion was
characterized by the determination of the maximum detach-
ment force (FD) and the work of detachment (WD). FD corres-
ponds to the peak of adhesion force with respect to the zero-
force level47 and relates to the force necessary to detach both
cells. WD is used to describe the energy needed for detaching
the cell probe and corresponds to the integrated area of
detachment below the zero-force level and the contour of the
F–d curve.47 WD results from adhesive elements from the
rupture of formed complexes and the mechanical component
resulting from cell deformation. After the maximum detach-
ment force occurs it is typical to find step-like events which
correspond to the unbinding or destruction of adhesive
units.47 During the detachment process surface membrane
nanotubes (tethers) can be extracted from the membrane. This
occurs when the lipid bilayer is pulled away from the cortical
cytoskeleton forming thin-like protrusions Q3.47 In these cases, in
which tethers are formed, the F–d curve is characterized by
forces that culminate with the detachment of the nanotube
from the cell.51 We have analysed tether formation after the
initial part of the F–d retraction curves (>3 µm); in the initial
part of the F–d curve other type of unbinding events are
dominant.30
Tumor–tumor cell adhesion results are presented in Fig. 5A
and S5.† FD, WD and tether extraction force decrease in the
presence of the PvD1 peptide. PvD1 ability in reducing the
adhesiveness of tumor cells might contribute for preventing or
retarding the formation of a solid tumor mass in the breast.
Damage to the tumor cells induces changes in the cell cytoske-
leton which contribute to perturbation in adhesion, to a lower
energy necessary to detach tumor cells from each other and to
changes in the tether extraction forces. The observation of
Fig. 6 The natural PvD1 defensin as an alternative therapeutic for metastatic breast cancer. (A, B, C) PvD1 structural features evidenced by homology
and sequence based predictions. Homology based simulation of PvD1 tri-dimensional structure was obtained using the I-Tasser online server.
56–58
PDB entry 2GL1, corresponding to the VrD2 defensin, was selected as a structural homology template. Tri-dimensional representations highlighting
the secondary structure motifs and basic/hydrophobic amino acid residue localization (A), and the Kyte–Doolittle hydropathy surface profile (B) are
shown from two orthogonal perspectives. The PvD1 amino acid residue sequence, secondary structure tendency per residue, Kyte–Doolittle
hydropathy plot (obtained using ExPaSy ProtScale with an 11 amino acid window)59 and solvent accessibility scores are also shown (C). Lines rep-
resented above the PvD1 sequence correspond to the predicted disulphide bonds between cysteine residues. Basic and hydrophobic amino acid resi-
dues are highlighted within the PvD1 sequence in red and blue, respectively. Random coils (c), β-sheets (e) and α-helices (h) are depicted as a full
line, an arrow and a rounded box, respectively. (D) The PvD1 putative mode of action in an in vivo context. PvD1 modulates the viability and cellular
adhesion properties of proliferating breast cancer cells. Damaged cells detach from the primary tumor site and are carried through the blood stream
to other organs. Circulating cancer cells become more susceptible to PvD1 action. Upon reaching the brain vasculature, protected by the BBB, circu-
lating damaged cells are unable to efficiently attach to the brain endothelial cell wall. PvD1 accumulates in endothelial cell membranes, which may
act as a latent reservoir. Consequently, cancer cell extravasation and metastasis are greatly impaired.
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tethers depends on the adhesive and elastic properties of the
cell52 and changes in their associated extraction forces have
been reported to translate alterations in membrane–cytoskele-
ton coupling.30,51 These observations consequently point to an
internal extensive cell damage caused by the PvD1 peptide that
challenges the tumor mass formation.
However, forming less adhesive breast cancer cells can
facilitate their entrance into blood circulation and, con-
sequently, spreading of metastasis formation stimulation. We
thus decided to investigate the changes occurring in FD and WD
after promoting contact between a HBMEC captured cell and
breast tumor cells (Fig. S3†). Low PvD1 concentrations, not
enough to induce low levels of cell death, are sufficient to
perturb the adhesion between tumor–brain endothelial cells.
The observed decrease in FD and WD is accompanied by an
increase in tether extraction force reflecting changes at the
cytoskeleton level of the HBMEC bound to the cantilever
(Fig. S5†). In this experimental setup, we were not able to obtain
good signal-to-noise F–d curves when treating tumor cells with
higher PvD1 concentration before interaction with brain cap-
tured cells. The degree of tumor cell destruction did not allow
proper contact with a single captured HBMEC. PvD1 is therefore
reducing cell-to-cell adhesion of both breast tumor cells among
themselves and between tumor cells and brain endothelial
cells. Metastatic adhesion to BBB cells is abrogated by PvD1.
PvD1-treated HBMEC interaction with a cantilever-bound
breast tumor cell resulted in decreased FD but higher WD at the
tether extraction force (Fig. 5 and S5†). These results reveal that
cell detachment in this case is not an abrupt event and that
intercellular connections are not disrupted simultaneously
which affects the area under the curve resulting in more energy
recruited in the process.53 Differences in WD account not only
for adhesion but also for mechanical components of the cell
which are difficult to completely isolate and in turn depend on
the cell’s viscoelastic properties.52 Changes in the HBMEC’s bio-
mechanics after PvD1 treatment will contribute to increasing
difficulty in BBB crossing by breast tumor cells.
Conclusions
In this study we show the activity of a natural peptide on
human breast and brain endothelial cells. PvD1 is a highly
cytotoxic peptide towards human breast cancer cells when
compared to HNP-1. AFM (imaging and SCFS), zeta potential
and fluorescence spectroscopy techniques reveal that PvD1
interacts differently with the cell membrane of normal and
tumor cells without inducing full membrane neutralization
prior to the onset of toxicity. The peptide reaches the interior
of the breast tumor cells inducing apoptotic events. In normal
brain cells PvD1 partially accumulates in the cellular mem-
brane resulting in perturbations on the membrane’s dipole
potential whose magnitude is proposed to be affected by the
different membrane features of these cells.
Our observations are supported by structural data obtained
from PvD1 peptide homology based prediction (Fig. 6).
54 PvD1
concentrates part of its hydrophobic amino acid residues on
one side of its surface. Albeit not being supercharged (pre-
dicted net charge +1.4), PvD1 has a high density of cationic
residues in a second separate region, thus being highly amphi-
pathic, which is in agreement with its ability to internalize the
cells and reach intracellular targets.
PvD1 is also a modulator of cell-to-cell adhesion since it is
not only promoting de-adhesion of tumor cells, reducing the
FD and WD necessary for this event to occur, but it also per-
turbs tumor cell adhesion to endothelial brain cells.
This is the first report on the biophysical characterization
of peptide–HBMEC interaction using zeta potential techniques
and AFM in imaging and SCFS modes. Suppression of cancer
cell adhesion is a promising strategy to debilitate cancer meta-
static spreading55 and our results indicate that PvD1 can be
explored as an alternative strategy to invasive approaches such
as breaching the BBB by preventing metastatic cells from
attaching to its surface.
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